About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

TTI-0102

Company: Thiogenesis Therapeutics, Inc.
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 24, 2026

Trial details

Withdrawn NCT NCT04262895

TTI-0102 for Veterans With TBI

Not yet reported, Not yet reported VA Office of Research and Development Est. completion 2021-10-15 1 site Stand-alone

Other conditions: Mild to Moderate TBI, Posttraumatic Stress Disorder
View official trial listing →
Withdrawn NCT NCT05212662

Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

Not yet reported Thiogenesis Therapeutics, Inc. Est. completion 2024-09-27 Stand-alone

Other conditions: COVID-19, COVID-19 Acute Respiratory Distress Syndrome
View official trial listing →
Completed NCT NCT06644534

A Study to Assess TTI-0102 vs Placebo in MELAS Patients

Not yet reported Thiogenesis Therapeutics, Inc. 9 participants Est. completion 2026-01-12 2 sites Stand-alone

Cardiovascular disease Other conditions: MELAS Syndrome
View official trial listing →
Not yet recruiting NCT NCT06990984

A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)

Not yet reported Thiogenesis Therapeutics, Inc. 18 participants Est. completion 2027-09 Stand-alone

Other conditions: Leigh Syndrome
View official trial listing →
Not yet recruiting NCT NCT07837726

Pilot Study of TTI-0102 in Cystinosis

Not yet reported Thiogenesis Therapeutics, Inc. 6 participants Est. completion 2027-03 Stand-alone

Other conditions: Nephropathic Cystinosis, Cystinosis
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT07837726

Also known as: TTI-0102, TTI-0102 (cysteamine-pantetheine disulfide)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.